Publication date: Jun 19, 2024
Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment-related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS-CoV2 vaccine in patients with follicular lymphoma receiving front-line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points. Commentary on: Lim et al. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024 (Online ahead of print). doi: 10. 1111/bjh. 19562.
| Concepts | Keywords |
|---|---|
| Chemoimmunotherapy | follicular lymphoma |
| Dampened | immune response |
| Online | SARS‐CoV‐2 vaccines |
| Vaccinations |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | time |
| disease | VO | vaccination |
| disease | MESH | blood cancer |
| disease | IDO | immune response |
| disease | MESH | lymphomas |
| disease | VO | vaccine |
| disease | MESH | follicular lymphoma |
| disease | MESH | COVID-19 |
Original Article
(Visited 1 times, 1 visits today)